Beyond the product
The data measuring the problem, the intellectual property status, and the path to market.
The problem is real and measurable
Direct observation revealed a need. Public data on therapy adherence revealed its scale: a systemic problem that affects millions of chronic patients every year and that has guided every design decision in Omiari.
50%
of patients do not follow therapy as prescribed
33-69%
of relapses in chronic patients caused by non-adherence
25%
of cardiac patients abandon treatment in the first year
200,000
premature deaths every year in the EU due to poor adherence
3 in 10
chronic patients in Italy take 5 or more medications (44% over 80)
20%
adherence rate in patients with asthma or COPD
The target market
Three access channels with distinct operational characteristics, in a growing European sector.
7.3Mactive family caregivers in Italy for elderly and chronic patients. Primary adoption channel for the home device.
8,045socio-healthcare residential facilities in Italy (nursing homes, disability facilities, mental health). B2B channel with centralized pharmacological therapy management.
19,997pharmacies in Italy. The pharmacist becomes an active node of the ecosystem: cartridge pickup, customization and adherence monitoring.
$66.2BEuropean market size in 2023, with an expected CAGR of 22.3% between 2024 and 2030.
Protected intellectual property
The Omiari project is supported by a solid intellectual property foundation. A first Italian patent for industrial invention has already been obtained and others are being released. The international PCT has had a 100% positive outcome.
Yoovant is seeking partners and investors in the pharma and medtech sectors to bring Omiari to market.
Italian patents
A first patent for industrial invention already obtained, others filed and being released.
International PCT
Patent Cooperation Treaty with a 100% positive verification report. No requests for additional information from the examiner.
The road traveled. And what remains.
From the first concept to the patent obtained: every milestone is the result of methodical work. The next steps define the path to market.
Percorso
Jan 2024
Needs analysis and market research
Feb 2024
Home device concept
Mar 2024
1st patent application (Italy)
May 2024
Pharmacy ecosystem concept
Sep 2024
Iterative prototyping
6v body · 10v cartridge
Oct 2024
Non-negative search report
Mar 2025
2nd patent with priority + PCT
Sep 2025
100% positive PCT · Software development begins
Feb 2026
First patent obtained
Apr 2026
Orizzonte
H1 2026
PCT national/regional phase begins
H2 2026
Firmware beta
Q1 2027
App beta
Q3 2027
Pilot testing
Q4 2027
Italy launch
2028
EU expansion · Nursing homes and pharmacies
Percorso
Jan 2024
Needs analysis and market research
Mar 2024
1st patent application (Italy)
Oct 2024
Non-negative search report
Sep 2025
100% positive PCT · Software development begins
Feb 2024
Home device concept
May 2024
Pharmacy ecosystem concept
Mar 2025
2nd patent with priority + PCT
Feb 2026
First patent obtained
Iterative prototyping
6v body · 10v cartridge
Sep 2024
Apr 2026
Orizzonte
H1 2026
PCT national/regional phase begins
Q1 2027
App beta
Q4 2027
Italy launch
H2 2026
Firmware beta
Q3 2027
Pilot testing
2028
EU expansion · Nursing homes and pharmacies
Are you in pharma or medtech?
If you are an investor or a company interested in bringing Omiari to market, now is the right time to talk.